Menu
Back to User profile » Dr Lee S. Schwartzberg
Papers published by Dr Lee S. Schwartzberg:
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
Navari RM, Schwartzberg LS
OncoTargets and Therapy 2018, 11:6459-6478
Published Date: 4 October 2018
Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S
ClinicoEconomics and Outcomes Research 2018, 10:493-500
Published Date: 3 September 2018
Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists
Gilmore J, D'Amato S, Griffith N, Schwartzberg L
Cancer Management and Research 2018, 10:1827-1857
Published Date: 3 July 2018
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
Rapoport BL, Aapro M, Chasen MR, Jordan K, Navari RM, Schnadig I, Schwartzberg L
Drug Design, Development and Therapy 2017, 11:2621-2629
Published Date: 5 September 2017
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
Schnadig ID, Agajanian R, Dakhil C, Gabrail N, Vacirca J, Taylor C, Wilks S, Braun E, Mosier MC, Geller RB, Schwartzberg L, Vogelzang N
Cancer Management and Research 2017, 9:179-187
Published Date: 19 May 2017
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
Puhalla S, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, Vahdat L
Breast Cancer: Targets and Therapy 2016, 8:231-239
Published Date: 7 December 2016